Patient-reported outcomes in vaccines research: relevance for decision-making

References

• Rappuoli R, De Gregorio E. Editorial overview: vaccines: novel technologies for vaccine development. Curr Opin Immunol. 2016;41:v–vii. doi:10.1016/j.coi.2016.07.001.
   PubMed Web of Science ®Google Scholar
• Melief CJM, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest. 2015;125(9):3401–12. doi:10.1172/JCI80009.
   PubMed Web of Science ®Google Scholar
• Zagadailov E, Fine M, Shields A. Patient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers. Am Health Drug Benefits. 2013;6(5):264–74.
   Google Scholar
• Hämeen-Anttila K, Komulainen J, Enlund H, Mäkelä M, Mäkinen E, Rannanheimo P, Sipilä R. Incorporating patient perspectives in health technology assessments and clinical practice guidelines. Res Social Adm Pharm. 2016;12(6):903–13. doi:10.1016/j.sapharm.2015.12.005.
   PubMed Web of Science ®Google Scholar
• Brotherton JML. HPV prophylactic vaccines: lessons learned from 10 years experience. Future Virol. 2015;10(8):999–1009. doi:10.2217/fvl.15.60.
   Web of Science ®Google Scholar
• Ehrlich HJ, Singer J, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Portsmouth D, Kistner O, Barrett PN. A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals. Clin Infect Dis. 2012;54(7):946–54. doi:10.1093/cid/cir959.
   PubMed Web of Science ®Google Scholar
• Kendrick P, Eldering G. A study in active immunization against pertussis. Am J Epidemiol. 1939;29-SectionB(3):133–53. doi:10.1093/oxfordjournals.aje.a118485.
   Google Scholar
• Vesikari T, Giaquinto C, Huppertz HI. Clinical trials of rotavirus vaccines in Europe. Pediatr Infect Dis J. 2006;25(1 Suppl):S42–7. doi:10.1097/01.inf.0000197565.45345.4e.
   PubMed Web of Science ®Google Scholar
• Curran D, Matthews S, Rowley SD, Young J-AH, Bastidas A, Anagnostopoulos A, Barista I, Chandrasekar PH, Dickinson M, El Idrissi M, et al. Recombinant zoster vaccine significantly reduces the impact on quality of life caused by herpes zoster in adult autologous hematopoietic stem cell transplant recipients: a randomized placebo-controlled trial (ZOE-HSCT). Biol Blood Marrow Transplant. 2019;25(12):2474–81. doi:10.1016/j.bbmt.2019.07.036.
   PubMed Web of Science ®Google Scholar
• Schmader KE, Johnson GR, Saddier P, Ciarleglio M, Wang WWB, Zhang JH, Chan ISF, Yeh SS, Levin MJ, Harbecke RM, et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc. 2010;58(9):1634–41. doi:10.1111/j.1532-5415.2010.03021.x.
   PubMed Web of Science ®Google Scholar
• Coplan PM, Schmader K, Nikas A, Chan ISF, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain. 2004;5(6):344–56. doi:10.1016/j.jpain.2004.06.001.
   PubMed Web of Science ®Google Scholar
• Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, Gundy C, Koller M, Petersen MA, Mirjam AG, et al. EORTC QLQ–C30 Reference Values; 2008. [accessed 2021 Jan 20]. https://www.eortc.org/app/uploads/sites/2/2018/02/reference_values_manual2008.pdf
   Google Scholar
• Ware JE, Kosinski M SF-36 physical & mental health summary scales: a manual for users of version 1. Quality Metric Incorporated, 2001.
   Google Scholar
• United States Department of Health and Human Services Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input. Guidance for industry, Dood and Drug Administration staff, and other stakeholders. MD: Food and Drug Administration, 2020. https://www.fda.gov/media/139088/download .
   Google Scholar
• Isaac M, Vamvakas S, Pavlovic M. EMA perspective on PRO instrument qualification and harmonization. First annual patient‐reported outcomes (pro) consortium workshop march 23, 2010 – Bethesda, MD: pro consortium. [accessed 2020 Aug 11]. https://c-path.org//wp-content/uploads/2013/09/2010PRO-Workshop-Isaac.pdf
   Google Scholar
• Powers JH 3rd, Howard K, Saretsky T, Clifford S, Hoffmann S, Llorens L, Talbot G. Patient-reported outcome assessments as endpoints in studies in infectious diseases. Clin Infect Dis. 2016;63(Suppl2):S52–6. doi:10.1093/cid/ciw317.
   PubMedGoogle Scholar
• United States Department of Health and Human Services Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. MD: Food and Drug Administration, 2009. [accessed 2020 Aug 11]. https://www.fda.gov/media/77832/download
   Google Scholar
• Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84. doi:10.1056/NEJMoa051016.
   PubMed Web of Science ®Google Scholar
• Yu J, Powers JH 3rd, Vallo D, Falloon J. Evaluation of efficacy endpoints for a phase IIb study of a respiratory syncytial virus vaccine in older adults using patient-reported outcomes with laboratory confirmation. Value Health. 2020;23(2):227–35. doi:10.1016/j.jval.2019.09.2747.
   PubMed Web of Science ®Google Scholar
• Doward LC, Gnanasakthy A, Baker MG. Patient reported outcomes: looking beyond the label claim. Health Qual Life Outcomes. 2010; 8: 89. doi:10.1186/1477-7525-8-89.
   Google Scholar
• Reeve BB, Wyrwich KW, Wu AW, Velikova G, Terwee CB, Snyder CF, Schwartz C, Revicki DA, Moinpour CM, McLeod LD, et al. ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res. 2013;22(8):1889–905. doi:10.1007/s11136-012-0344-y.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Gnanasakthy A, Weinfurt K. Documenting the rationale and psychometric characteristics of patient reported outcomes for labeling and promotional claims: the PRO evidence dossier. Qual Life Res. 2007;16(4):717–23. doi:10.1007/s11136-006-9153-5.
   PubMed Web of Science ®Google Scholar
• Curran D, Oostvogels L, Heineman T, Matthews S, McElhaney J, McNeil S, Diez-Domingo J, Lal H, Andrews C, Athan E, et al. Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50 years and older. J Gerontol A Biol Sci Med Sci. 2019;74(8):1231–8. doi:10.1093/gerona/gly150.
   PubMed Web of Science ®Google Scholar
• Hauber AB, González JM, Groothuis-Oudshoorn CGM, Prior T, Marshall DA, Cunningham C, Ijzerman MJ, Bridges JFP. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19(4):300–15. doi:10.1016/j.jval.2016.04.004.
   PubMed Web of Science ®Google Scholar
• Wells CD, Murrill WB, Arguedas MR. Comparison of health-related quality of life preferences between physicians and cirrhotic patients: implications for cost-utility analyses in chronic liver disease. Dig Dis Sci. 2004;49(3):453–8. doi:10.1023/b:ddas.0000020502.46886.c1.
   PubMed Web of Science ®Google Scholar
• Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan AW, King MT, Hunn A, Bottomley A, Regnault A, Chan AW, et al. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension. Jama. 2018;319(5):483–94. doi:10.1001/jama.2017.21903.
   PubMed Web of Science ®Google Scholar
• Coens C, Pe M, Dueck AC, Sloan J, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, et al. International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL consortium. Lancet Oncol. 2020;21(2):e83–96. doi:10.1016/s1470-2045(19)30790-9.
   PubMed Web of Science ®Google Scholar
• Callegaro A, Curran D, Matthews S. Burden-of-illness vaccine efficacy. Pharm Stat. 2020;19(5):636–45. doi:10.1002/pst.2020
   PubMed Web of Science ®Google Scholar
• Public Health England. Vaccination against shingles. Information for healthcare professionals. London, UK: Public Health England, 2018 [accessed 2020 Sep 24]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/696498/Shingles_information_for_healthcare_professionals.pdf
   Google Scholar
• EUnetHTA Joint Action 2. 2015. Guideline. Endpoints used for relative effectiveness assessment. Composite endpoints. [accessed 2020 Sep 24]. https://eunethta.eu/wp-content/uploads/2018/03/composite_endpoints.pdf .
   Google Scholar
• United States Food and Drug Administration. Principles for Selecting, Developing, Modifying, and Adapting Patient Reported Outcome Instruments for Use in Medical Device Evaluation. Draft Guidance for Industry and Food and Drug Administration Staff, And Other Stakeholders. MD: U.S. Department of Health and Human Services; 2020 [accessed 2020 Sep 24]. https://www.fda.gov/media/141565/download
   Google Scholar
• Betsuyaku T, Kato M, Fujimoto K, Hagan G, Kobayashi A, Hitosugi H, James M, Jones PW. A study to assess COPD symptom-based management and to optimise treatment strategy in Japan (COSMOS-J) based on GOLD 2011. Int J Chron Obstruct Pulmon Dis. 2013;8:453–9. doi:10.2147/COPD.S48298.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD. 2019 Global initiative for Chronic Obstructive Lung Disease, 2019. [accessed 2020 Aug 11]. https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf .
   Google Scholar
• Grove BE, Ivarsen P, de Thurah A, Schougaard LM, Kyte D, Hjøllund NH. Remote follow-up using patient-reported outcome measures in patients with chronic kidney disease: the PROKID study - study protocol for a non-inferiority pragmatic randomised controlled trial. BMC Health Serv Res. 2019;19(1):631. doi:10.1186/s12913-019-4461-y.
   PubMed Web of Science ®Google Scholar
• Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34(6):557–65. doi:10.1200/JCO.2015.63.0830.
   PubMed Web of Science ®Google Scholar
• Curran D, Kim JH, Matthews S, Dessart C, Levin MJ, Oostvogels L, Riley ME, Schmader KE, Cunningham AL, McNeil SA, Schuind AE, et al. Recombinant zoster vaccine is efficacious and safe in frail individuals. J Am Geriatr Soc. 2020 Nov 16. doi:10.1111/jgs.16917.
   PubMed Web of Science ®Google Scholar
• Curran D, Schmidt-Ott R, Schutter U, Simon J, Anastassopoulou A, Matthews S. Impact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or above. BMC Infect Dis. 2018;18(1):496. doi:10.1186/s12879-018-3395-z.
   PubMedGoogle Scholar
• Van Oorschot D, Anastassopoulou A, Poulsen Nautrup B, Varghese L, von Krempelhuber A, Neine M, Lorenc S, Curran D. Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old. Hum Vaccin Immunother. 2019;15(1):34–44. doi:10.1080/21645515.2018.1509645.
   PubMed Web of Science ®Google Scholar
• Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381(9868):752–62. doi:10.1016/s0140-6736(12)62167-9.
   PubMed Web of Science ®Google Scholar
• Curran D, Andrew MK, Levin MJ, Turriani E, Matthews S, Fogarty C, Klein NP, Grupping K, Oostvogels L, Schmader KE. Evaluation of two frailty indices, with practical application in a vaccine clinical trial. Hum Vaccin Immunother. 2019;15(12):2960–8. doi:10.1080/21645515.2019.1622974.
   PubMed Web of Science ®Google Scholar
• Branche A, Granieri E, Walsh E, Finelli L, Greendyke W, Falsey AR, Barrett A, Vargas C, Saiman L. 733. Incidence and evaluation of the change in functional status associated with respiratory syncytial virus infection in hospitalized older adults. Open Forum Infect Dis. 2018;5(Suppl1):S263. doi:10.1093/ofid/ofy210.740.
   Google Scholar
• Hernández-Guerra M, González-Méndez Y, de Molina P, Gimeno-García AZ, Carrillo M, Casanova C, Pumarola T, Jimenez A, Hernández-Porto M, Torres A, et al. Immunogenicity and acceptance of influenza A (H1N1) vaccine in a cohort of chronic hepatitis C patients receiving pegylated-interferon treatment. PloS One. 2012;7(11):e48610. doi:10.1371/journal.pone.0048610.
   PubMed Web of Science ®Google Scholar
• Schmader KE, Levin MJ, Grupping K, Matthews S, Butuk D, Chen M, Idrissi ME, Fissette LA, Fogarty C, Hartley P, et al. The impact of reactogenicity after the first dose of recombinant zoster vaccine on the physical functioning and quality of life of older adults: an open-label, phase III trial. J Gerontol A Biol Sci Med Sci. 2019;74(8):1217–24. doi:10.1093/gerona/gly218.
   PubMed Web of Science ®Google Scholar